Client of a consultant lobbyist
Vertex Pharmaceuticals (Canada) Inc.
- Meetings this Parliament
- 0
- With MPs
- 0
- Since Nov 2021
- 0
- Active registrations
- 1
Lobbying by Vertex Pharmaceuticals (Canada) Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Consultant In effect since Sep 14, 2026
Consultant Ghita Morsli of 3Sixty Public Affairs Inc.
Consultant lobbyists
- Ghita Morsli
Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (8)Hide details
- Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
- Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
- Implementation of Canada's action plan for pain and federal initiatives related to pain management.
- Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
- Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
- Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
- Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy
- Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
Registration 966506-387927-1. Look it up in the official Registry
Reported meetings
No meetings reported since November 2021.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.